Urinary tract infection (UTI) refer to a common bacterial infection disease, that occurs in either a community or healthcare setting. Clinically, UTIs are categorized as uncomplicated and complicated. Uncomplicated UTIs typically occur in a healthy adult non-pregnant woman and have no structural or neurological urinary tract abnormalities; these infections are differentiated into cystitis and pyelonephritis.
Explore report sample at: https://www.psmarketresearch.com/market-analysis/utis-therapeutics-pipeline/report-sample
UTIs are caused by both gram-negative and gram-positive bacteria, as well as by certain fungi. Gram-negative rod Escherichia coli is the most common cause of UTIs in all settings and is transmitted by person-to-person direct contact and the fecal-oral route. The study analyzed that Urinary Tract Infections therapeutics pipeline comprises approximately 40 drug candidates in different stages of development.
It has been observed that a majority of the companies in the UTIs therapeutic pipeline are developing drug candidates by using advanced technologies and these drug candidates have further shown positive efficacy in the clinical stage of development. For instance, MULTIPHORE Drug Design platform developed by Talon Pharmaceuticals Inc., specifies the complexity of the disease in nature. The above-mentioned technology is designed to identify the drug that interacts with multiple disease target through careful incorporation of multiple pharmacophores into a single molecule or through unique combination of different mechanisms of action implicated in the disease state.
Browse report at: https://www.psmarketresearch.com/market-analysis/utis-therapeutics-pipeline
Some of the key players involved in the development of UTIs therapeutics pipeline include Achaogen Inc., AmpliPhi Biosciences Corporation, and Iterum Therapeutics Limited.
Explore report sample at: https://www.psmarketresearch.com/market-analysis/utis-therapeutics-pipeline/report-sample
UTIs are caused by both gram-negative and gram-positive bacteria, as well as by certain fungi. Gram-negative rod Escherichia coli is the most common cause of UTIs in all settings and is transmitted by person-to-person direct contact and the fecal-oral route. The study analyzed that Urinary Tract Infections therapeutics pipeline comprises approximately 40 drug candidates in different stages of development.
It has been observed that a majority of the companies in the UTIs therapeutic pipeline are developing drug candidates by using advanced technologies and these drug candidates have further shown positive efficacy in the clinical stage of development. For instance, MULTIPHORE Drug Design platform developed by Talon Pharmaceuticals Inc., specifies the complexity of the disease in nature. The above-mentioned technology is designed to identify the drug that interacts with multiple disease target through careful incorporation of multiple pharmacophores into a single molecule or through unique combination of different mechanisms of action implicated in the disease state.
Browse report at: https://www.psmarketresearch.com/market-analysis/utis-therapeutics-pipeline
Some of the key players involved in the development of UTIs therapeutics pipeline include Achaogen Inc., AmpliPhi Biosciences Corporation, and Iterum Therapeutics Limited.
About
P&S Intelligence
P&S
Intelligence, a brand of P&S Market Research, is a provider of market
research and consulting services catering to the market information needs of
burgeoning industries across the world. Providing the plinth of market
intelligence, P&S as an enterprising research and consulting company,
believes in providing thorough landscape analyses on the ever-changing market
scenario, to empower companies to make informed decisions and base their
business strategies with astuteness.
Contact:
P&S Intelligence
Toll-free: +1-888-778-7886
(USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Connect with us: LinkedIn | Twitter | Google + | Facebook
